A Phase 2 interventional study of INV-102 in Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy and Diabetic Retinopathy, sponsored by Invirsa, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Invirsa, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.
Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 159th largest by enrollment of the 196 interventional ones that give a count, is one of 11 that started in 2024, is one of 52 in phase 2, and was the 233rd registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 22+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Digital Diagnostics, Inc. · Sites in United States
Ages 22+ · Healthy volunteers
BioAge Labs, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
267 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 64 · Phase 3 35 · Phase 4 20
First in 1992; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 80 across 484 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 72 across the 196 interventional studies, 161 across the 70 observational. Of the 188 that completed or were terminated, 66 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 267 have an industry lead sponsor. The 10 most frequent:
Invirsa, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Invirsa, Inc. has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetic Retinopathy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235085Phase 3Ocular Therapeutix, Inc.A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | 2027-03 |
| NCT06191094University of Colorado, DenverPre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT05463289Johns Hopkins UniversityACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 | 2026-12-30 |
Add all 19 to your calendar (.ics) → With an account.
Among the 267 studies in Diabetic Retinopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 2].
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INV-102 0.7% Ophthalmic Solution given three times daily (TID) for 2 weeks followed by twice daily (BID) for 10 weeks
Drug: INV-102
INV-102 0.7% Ophthalmic Solution given three times daily (TID) for 2 weeks followed by twice daily (BID) for 6 weeks
Drug: INV-102
0.7% Ophthalmic Solution
Change from baseline in the Early Treatment Diabetic Retinopathy (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score
Graded by an independent central reading center using Wide-field Color Fundus Photography. The DRSS divides diabetic retinopathy into levels ranging from absence of retinopathy (score = 10) to advanced retinopathy (score = 85). The scale is used to describe overall retinopathy severity as well as the change in severity over time.
Time frame: Day 84 (Part 1) and Day 56 (Part 2)
Change from baseline in central subfield thickness (Part 2 only)
Measured using spectral domain optical coherence tomography (SD-OCT) and determined by an independent central reading center.
Time frame: Day 56
Change from baseline in macular volume
Measured using spectral domain optical coherence tomography (SD-OCT)
Time frame: Day 84 (Part 1) and Day 56 (Part 2)
Change from baseline in subfield thickness
Mean retinal thickness in each of the regional subfields of the ETDRS grid, measured using SD-OCT
Time frame: Day 84 (Part 1) and Day 56 (Part 2)
Change from baseline in the retinal thickness at the thickest point of the subfield thickness
Measured using SD-OCT in each of the regional subfields of the ETDRS grid
Time frame: Day 84 (Part 1) and Day 56 (Part 2)
Change in best corrected visual acuity (BCVA) (Part 2 only)
Time frame: Day 56
Ran from Sep 2024 to primary completion in Sep 2025, 12 months.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 12 months is below that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: INV-102
Invirsa, Inc.